Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Abstract Background The long-term safety was assessed in patients with psoriatic arthritis who were treated with ixekizumab in three clinical trials (SPIRIT-P1/-P2/-P3). Methods Integrated safety data from three trials (controlled and uncontrolled), including two pivotal phase 3, randomized, double-...

Full description

Bibliographic Details
Main Authors: Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Arthritis Research & Therapy
Subjects:
Ixekizumab
Safety
Psoriatic arthritis
Inflammatory bowel disease
Major adverse cardiovascular events
Online Access:https://doi.org/10.1186/s13075-020-2099-0

Internet

https://doi.org/10.1186/s13075-020-2099-0

Similar Items